Superior Vena Cava Syndrome in the Cancer Patient: A Case Study

ELAINE KINNARD, MSN, CNP

Patients with lung cancer are at risk for superior vena cava syndrome (SVCS). Here we present a case study of a gentleman with small cell lung cancer who develops a swollen neck, edema, and dyspnea upon exertion. Would you, as the advanced practitioner, recognize the problem?

Superior vena cava syndrome is a rare oncologic emergency that occurs in roughly 15,000 persons in the United States each year (Wilson, Deterbeck, & Yahalom, 2007). Superior vena cava syndrome has a distinct clinical presentation and can be life threatening. It is found in 3.8% of lung cancer patients at the time of diagnosis and more frequently associated with superior vena cava obstruction (Rowell & Gleeson, 2002). Superior vena cava syndrome is caused by cancer 95% of the time; the other 5% of cases could be related to thrombosis from insertion of venous catheters or pacemaker wires (National Cancer Institute, 2011). Characteristically, the onset of symptoms in SVCS occurs gradually over weeks to months (Parra, Rodas, Bartnik, & Puente, 2011).

 PATHOPHYSIOLOGY

The superior vena cava (SVC) is a short large-diameter vein (about 7 cm long) that carries deoxygenated blood from the upper half of the body to the heart's right atrium (Figure 1). The SVC is located in the anterior right superior mediastinum, surrounded by the sternum, ribs, vertebral bodies, and aorta (Nunnelee, 2007). When the SVC is compressed, blood flows through the collateral vascular network to create venous congestion and edema.
collaterals that dilate to accommodate blood flow. This results in the characteristic superficial blue vessels on the skin surface (Wilson et al., 2007). The obstruction causes distention of the axillary, subclavian, and jugular veins. The obstruction can increase edema in the luminal diameter of the pharynx and larynx, which causes the patient to develop stridor. Cerebral edema, which may result in headache and confusion, could occur and lead to cerebral ischemia and possible death (Lewis et al., 2011).

**DIAGNOSIS**

Superior vena cava syndrome consists of various symptoms due to compression of the SVC (Leeper et al., 2011). Early signs and symptoms include cough, dyspnea, hoarseness, chest pain, jugular vein distention, and edema of the hands, face, and/or neck. Family members may note these signs to be more prevalent in the early morning. More advanced signs and symptoms can be life threatening, such as respiratory distress, stridor, mental status changes, syncope, and cyanosis of the face and upper body (Colen, 2008).

Superior vena cava syndrome caused by cancer is a poor prognostic sign that is associated with high mortality. The advanced practitioner caring for a cancer patient with these symptoms needs to recognize the life-threatening diagno-
sis of SVCS as a priority consideration in the list of differential diagnoses. Additional differential diagnoses to be considered include pulmonary effusion, thrombosis, and catheter placement obstruction. The signs and symptoms of other possible diagnoses can be ruled out in the outpatient clinic if one understands and looks for the hallmarks of SVCS.

A thorough history and physical examination are critical, focusing on signs and symptoms of SVCS. Advanced practitioners should specifically assess for dyspnea, upper extremity swelling, nonproductive cough, facial swelling, and collateral veins on the neck or upper chest and/or under the tongue (Nunnelee, 2007). A late symptom of this condition is Horner’s syndrome, identified by ptosis of the upper and lower eyelids, an ipsilateral constricted pupil, and/or loss of sweating on one side of the face (Aziz, 2010).

A chest CT with IV contrast or MRI can be performed to assist in evaluating the underlying pathology, which most likely will be tumor. The gold standard for evaluation of the SVC is a venogram (Lewis et al., 2011). The SVC diameter and length of the SVC stenosis/occlusion can be measured with these studies to help plan for endovascular treatment if warranted (Lepper et al., 2011).

**TREATMENT**

Because SVCS is a life-threatening emergency, early diagnosis and appropriate intervention are imperative. Treatment for SVCS depends on the cause and prognosis of the underlying disease (Battal et al., 2009). The goal of managing SVCS in malignancy cases is to relieve symptoms and treat the underlying causes (Sommers, 2012). If the cancer prognosis for the patient is poor, then it would be appropriate to relieve symptoms and offer comfort measures. In most cases where SVCS is caused by a malignancy, chemotherapy or radiation is the treatment of choice (Cho, Janho, & Mohan, 2011). Vascular thrombosis may require thrombolytic agents. Endovascular management is another well-recognized treatment for malignant SVCS. A stent is placed in the SVC to increase the blood flow through the stenosis (Cho et al., 2011).

There are some non–evidence-based treatments for SVCS available. The use of steroids and diuretics is still being studied, yet so far they have not been shown to be effective in reducing symptoms (Lewis et al., 2011).

**CONCLUSION**

Superior vena cava syndrome occurs infrequently, but it can be a life-threatening oncologic emergency. The advanced practitioner needs to be aware of patients at high risk for this condition. Early recognition of signs and symptoms of impending SVCS is essential in an ambulatory setting. Accurate diagnosis and aggressive management of the underlying cause of the SVCS (tumor or clot) should be timely and are imperative for patients to achieve positive outcomes. Randomized controlled trials are lacking for most treatment options seeking to directly treat the signs and symptoms of SVCS (Lepper et al., 2011).

**DISCLOSURE**

The author has no conflicts of interest to disclose.

**REFERENCES**

Aziz, Z. (2010). Case study—An unusual case of unequal pupils. General Practitioner, 36, 1.

Battal, B., Bozlar, U., Ors, F., Nikolla, S., Tasar, M., & Tayfun, C. (2009). Superior vena cava syndrome caused by a bronchogenic cyst: Report of a case. Journal of Pulmonary Medicine, 11, 8–9.

Cho, T., Janho, K., & Mohan, I. (2011). The role of stenting the superior vena cava syndrome in patients with malignant disease. Angiology, 62(3), 248–252. http://dx.doi.org/10.1177/0003319710382772

Colen, F. (2008). Oncologic emergencies: Superior vena cava syndrome, tumor lysis syndrome, and spinal cord compression. Journal of Emergency Nursing, 34, 535–537. http://dx.doi.org/10.1016/j.jen.2007.09.012

Lepper, P., Ott, S., Hoppe, H., Schumann, C., Stammberger, U., Bugalho, A.,...Hamacher, J. (2011). Superior vena cava syndrome in thoracic malignancies. Respiratory Care, 56(5), 653–666. http://dx.doi.org/10.4187/respcare.09947

Lewis, M. A., Hendrickson, A. W., & Moynihan, T. J. (2011). Oncologic emergencies: Pathophysiology, presentation, diagnosis, and treatment. CA: A Cancer Journal for Clinicians, 61, 287–310.http://dx.doi.org/10.3322/caac.20124

Colen, F. (2008). Oncologic emergencies: Superior vena cava syndrome, tumor lysis syndrome, and spinal cord compression. Journal of Emergency Nursing, 34, 535–537. http://dx.doi.org/10.1016/j.jen.2007.09.012

Parra, M. W., Rodas, E. B., Bartnik, J. P., & Puente, I. (2011). Surviving a delayed trans-diaphragmatic hepatic rupture complicated by an acute superior vena cava and thoracic compartment syndromes. Journal of Emergencies, Trauma, and Shock, 4(3), 425. http://dx.doi.org/10.4103/0974-270X.83879

Rowell, N. P., & Gleeson, F. V. (2002). Steroids, radiotherapy, chemotherapy, and stents for superior vena caval obstruction in carcinoma of the bronchus: A systematic review. Clinical Oncology, 14(5), 338–351. http://dx.doi.org/10.1053/clon.2002.0095

Sommers, R. (2012). Dyspnea in the oncology patient. Journal of the Advanced Practitioner in Oncology, 3(1), 59–60.

Wilson, L., Detterbeck, F., & Yahalom, J. (2007). Superior vena cava syndrome with malignant causes. New England Journal of Medicine, 356(18), 1862–1869. http://dx.doi.org/10.1056/NEJMcp067190